Text this: Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)

 _    _    __   __    _____      ___     _    _   
| |  | ||  \ \\/ //  |__  //    / _ \\  | |  | || 
| |/\| ||   \ ` //     / //    / //\ \\ | |/\| || 
|  /\  ||    | ||     / //__  |  ___  |||  /\  || 
|_// \_||    |_||    /_____|| |_||  |_|||_// \_|| 
`-`   `-`    `-`'    `-----`  `-`   `-` `-`   `-`